Scientific Online Resource System

International Bulletin of Otorhinolaryngology

A clinical case of transition from Acute Psychotic Substance Abuse Disorder to Schizophrenia

D. Avramov

Abstract

Psychotic disorders due to psychoactive substances (PASs) are increasingly common in clinical practice. Numerous studies have shown that illicit PASs can cause transient psychotic symptoms, acute psychotic states, and subsequently the full-blown clinical picture of paranoid schizophrenia.
Common comorbidity indicates common pathogenetic mechanisms of psychosis and addiction. The presented case demonstrates the complex impact of possibly different risk factors – genetic, neurodevelopmental and exogenous, such as systemic combined abuse of PASs since adolescence. Understanding the alleged biological pathways between the effects of PASs, the first episode of psychosis, and the risk of subsequently developing schizophrenia is particularly important for future prevention and early therapeutic interventions in predisposed individuals.

Keywords

psychoactive substances, acute psychotic disorder, comorbidity, risk factors, paranoid schizophrenia

Full Text


References

European Drugs Report 2025 National Focal Point on Drugs and Drug Addiction. https://www.nfp-drugs.bg/european-drugreport-2025-bg/.

Fiorentini A, Cantù F, Crisanti C et al. (2021) Substance-Induced Psychoses: An Updated LiteratureReview. Front. Psychiatry 12:694863.doi: 10.3389/fpsyt.2021.694863;

Lisa Dixon, Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes,Schizophrenia Research,Volume 35, Supplement 1,1999, Pages S93-S100, ISSN 0920-9964, https://doi.org/10.1016/S0920-9964(98)00161(https://www.sciencedirect.com/science/article/pii/S0920996498001613)

Opsal A, Clausen T, Kristensen O. et al. Involuntary hospitalization of first-episode psychosis with substance abuse during a 2-year follow-up. Acta Psychiatr Scand. 2011 Sep;124(3):198-204. doi: 10.1111/j.1600-0447.2011.01700.x. Epub 2011 Mar 21. PMID:21418161;

Zdeněk Fišar Biological hypotheses, risk factors, and biomarkers of schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 120, 2023, 110626, ISSN 0278-5846, https://doi.org/10.1016/j.pnpbp.2022.110626,(https://www.sciencedirect.com/science/article/pii/S027858462200118X)

Valerio Ricci, Franca Ceci, Francesco Di Carlo et al. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation, Psychiatry Research, Volume 320, 2023,115053, ISSN 0165-1781,https://doi.org/10.1016/j.psychres.2023.115053.(https://www.sciencedirect.com/science/article/pii/S0165178123000069)

Ayman Alzu’bi, Ejlal Abu-El-Rub, Fatimah Al. et al Delineating the molecular mechanisms of hippocampal neurotoxicity induced by chronic administration of synthetic cannabinoid AB-FUBINACA in mice, NeuroToxicology, Volume 103, 2024, Pages 50-59, ISSN 0161-813X, https://doi.org/10.1016/j.neuro.2024.05.009.

Little R, D’Mello D. A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis. Innov Clin Neurosci. 2022 Jul-Sep;19(7-9):38-43. PMID: 36204167; PMCID: PMC9507146.

Isis M. Ornelas, Felipe A. Cini, Isabel Wießner et al. Nootropic effects of LSD: Behavioral, molecular and computational evidence, Experimental Neurology,Volume 356, 2022,114148, ISSN 0014-4886, https://doi.org/10.1016/j.expneurol.2022.114148.(https://www.sciencedirect.com/science/article/pii/S001448862200173X).

Annalisa Post, Mary E. Norton, Ana Monteagudo et al. American Journal of Obstetrics and Gynecology, Volume 223, Issue 6,2020,Pages B47-B50, ISSN 0002-9378,https://doi.org/10.1016/j.ajog.2020.08.187. (https://www.sciencedirect.com/science/article/pii/S000293782100171X)




DOI: http://dx.doi.org/10.14748/orl.v20i4.10372

Refbacks

Font Size


|